Pfizer's Experimental Drug Fails to Meet Primary Endpoint in Lung Cancer Trial
📊 PFE — Piyasa Yorumu
▼ down · 70%Pfizer's failure to meet the primary goal in its experimental lung cancer drug trial may negatively impact the company's stock. The RSI14 value is at a low level of 35.45, and the MACD indicator is also in the negative zone, potentially indicating a short-term decline. However, the SMA20 and SMA50 values are still maintaining the stock's support levels. Therefore, a short-term decline is expected, but an extreme decline is unlikely.
📊 GOOGL — Piyasa Yorumu
■ neutral · 60%GOOGL shares are not directly impacted by the failure of Pfizer's experimental drug. However, overall market sentiment may turn negative. The RSI14 stands at 35, indicating the stock may be oversold. The MACD and MACD signal line are in negative territory, but this may not be sufficient to determine the stock's short-term direction. The short-term performance of GOOGL shares could vary depending on overall market conditions and developments in the technology sector.